- Switzerland
- February 11, 2022
WEF Global Risk Report 2022: There are good news between the gloomy outlook
The Global Risks Report 2022 presents the results of the latest WEF Global Risks Perceptio…
Globalance Footprint
Loading…
The Health score of this Portfolio is 54
Health
The Globalance Footprint® shows you the impacts of these assets around the world - individually and at a glance. Our framework is simple and objective. Using nine themes, we assess your contribution to sustainable foundations for economic prosperity, the future viability of society and the preservation of our natural resources.
54
Health
28%
of this invested capital features an adverse footprint in Health.
36%
of this invested capital features a balanced footprint in Health.
36%
of this invested capital features a positive footprint in Health.
What's at stake
A smoothly functioning healthcare system is a fundamental building block for a sustainable society. Through the world, healthcare schemes are under pressure, either because they can’t assure proper medical care or because the related costs are exploding. The «access to medicine» debate focuses on broadening the range of treatments even for rare diseases. For its part, the food industry is being called upon to provide healthy nourishment and promote wellbeing.
Health Scores of your Assets
Portfolio Footprint Score
Data source: Globalance
What am I looking at?
The graph shows you the score for each asset. The shape of each asset is its stylized Footprint-Profile.
Asset Name | Health | Society | Total Footprint | % of portfolio | |
|---|---|---|---|---|---|
| Zoetis, Inc. Class A | 100 | 100 | 87 | 0.2% | |
| UnitedHealth Group Incorporated | 100 | 100 | 95 | 1.4% | |
| Molina Healthcare, Inc. | 100 | 100 | 93 | 0.1% | |
| Mettler-Toledo International Inc. | 100 | 100 | 97 | 0.1% | |
| Laboratory Corporation of America Holdings | 100 | 100 | 95 | 0.1% |
Why does it matter
Global Challenges
Undersupply of medicines and healthcare facilities
Rising direct costs of the healthcare system
Higher indirect costs to the economy
The spread of rare diseases
Recalls of deficient products
Health risks
Global Goals
Access to affordable healthcare
Diversity of therapies and medical technologies even for “orphan” diseases
New business models that incorporate differential pricing
Safety and quality of medicines
Relevance for Investors
Access to medicine in the developing world is improving, which results in higher life expectancy. Pharmaceutical companies have a direct influence on the speed of this development through pricing and patent policy. Pharmaceutical companies follow an economic agenda along with ethical considerations, when making medicine available to poor population segments. There is a trade-off between making a product available at low cost (and thus low profit) and purely commercial considerations. Growing demand for pharmaceuticals in many countries (led by Brazil, Russia, India and China) is recognized as a major driver for the industry today. Healthier populations are more productive and contribute to economic growth. Companies which make their products available to low-income population segments will profit from brand recognition and trust as developing economies start to grow and can increasingly afford to pay higher prices.
Latest Insights
Globalance assesses and comments: With our Insights, we show you what the developments in the world mean for your assets. The focus is on future-oriented answers to major challenges.